[1]
|
Han, B., Zheng, R., Zeng, H., et al. (2024) Cancer Incidence and Mortality in China, 2022. Journal of the National Cancer Center, 4, 47-53. https://doi.org/10.1016/j.jncc.2024.01.006
|
[2]
|
Herbst, R.S., Heymach, J.V. and Lippman, S.M. (2008) Lung Cancer. The New England Journal of Medicine, 359, 1367-1380. https://doi.org/10.1056/NEJMra0802714
|
[3]
|
Wen, S., Dai, L., Wang, L., et al. (2019) Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. The Oncologist, 24, e1070-e1081. https://doi.org/10.1634/theoncologist.2018-0572
|
[4]
|
Furge, K.A., Zhang, Y.W. and Vande Woude, G.F. (2000) Met Receptor Tyrosine Kinase: Enhanced Signaling through Adapter Proteins. Oncogene, 19, 5582-5589. https://doi.org/10.1038/sj.onc.1203859
|
[5]
|
Vuong, H.G., Ho, A.T.N., Altibi, A.M.A., et al. (2018) Clinicopathological Implications of MET Exon 14 Mutations in Non-Small Cell Lung Cancer—A Systematic Review and Meta-Analysis. Lung Cancer, 123, 76-82. https://doi.org/10.1016/j.lungcan.2018.07.006
|
[6]
|
Wang, N., Zhu, Y., Wu, Y., et al. (2022) MET Overexpression in EGFR L858R Mutant Treatment-Naïve Advanced Lung Adenocarcinoma Correlated with Poor Prognosis: A Real-World Retrospective Study. Journal of Cancer Research and Clinical Oncology, 149, 3219-3228. https://doi.org/10.1007/s00432-022-04225-5
|
[7]
|
Cortot, A.B., Kherrouche, Z., Descarpentries, C., et al. (2017) Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. Journal of the National Cancer Institute, 109, Article djw262. https://doi.org/10.1093/jnci/djw262
|
[8]
|
Liu, Y. (1998) The Human Hepatocyte Growth Factor Receptor Gene: Complete Structural Organization and Promoter Characterization. Gene, 215, 159-169. https://doi.org/10.1016/S0378-1119(98)00264-9
|
[9]
|
Organ, S.L. and Tsao, M.S. (2011) An Overview of the c-MET Signaling Pathway. Therapeutic Advances in Medical Oncology, 3, S7-S19. https://doi.org/10.1177/1758834011422556
|
[10]
|
Sonnenberg, E., Meyer, D., Weidner, K.M., et al. (1993) Scatter Factor/Hepatocyte Growth Factor and Its Receptor, the c-Met Tyrosine Kinase, Can Mediate a Signal Exchange between Mesenchyme and Epithelia during Mouse Development. Journal of Cell Biology, 123, 223-235. https://doi.org/10.1083/jcb.123.1.223
|
[11]
|
Kong-Beltran, M., Stamos, J. and Wickramasinghe, D. (2004) The Sema Domain of Met Is Necessary for Receptor Dimerization and Activation. Cancer Cell, 6, 75-84. https://doi.org/10.1016/j.ccr.2004.06.013
|
[12]
|
Cooper, C.S., Park, M., Blair, D.G., et al. (1984) Molecular Cloning of a New Transforming Gene from a Chemically Transformed Human Cell Line. Nature, 311, 29-33. https://doi.org/10.1038/311029a0
|
[13]
|
Guo, B., Cen, H., Tan, X., et al. (2014) Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures. PLOS ONE, 9, e99399. https://doi.org/10.1371/journal.pone.0099399
|
[14]
|
Leardini, D., Messelodi, D., Muratore, E., et al. (2022) Role of CBL Mutations in Cancer and Non-Malignant Phenotype. Cancers, 14, Article 839. https://doi.org/10.3390/cancers14030839
|
[15]
|
Kong-Beltran, M., Seshagiri, S., Zha, J., et al. (2006) Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer. Cancer Research, 66, 283-289. https://doi.org/10.1158/0008-5472.CAN-05-2749
|
[16]
|
Frampton, G.M., Ali, S.M., Rosenzweig, M., et al. (2015) Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discovery, 5, 850-859. https://doi.org/10.1158/2159-8290.CD-15-0285
|
[17]
|
Mazieres, J., Vioix, H., Pfeiffer, B.M., et al. (2023) MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. Clinical Lung Cancer, 24, 483-497. https://doi.org/10.1016/j.cllc.2023.06.008
|
[18]
|
Recondo, G., Guo, R., Cravero, P., et al. (2020) Clinical Characteristics, Genomic Features, and Recurrence Risk of Early-Stage MET Exon 14 Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology, 38, 9042. https://doi.org/10.1200/JCO.2020.38.15_suppl.9042
|
[19]
|
Lamberti, G., Li, Y., Spurr, L., et al. (2019) P2.04-32 Comparison of Clinicopathological and Genomic Characteristics between NSCLCs with a PD-L1 Tumor Proportion Score of ≥90% vs. <1%. Journal of Thoracic Oncology, 14, S720-S721. https://doi.org/10.1016/j.jtho.2019.08.1537
|
[20]
|
Hellman, A., Zlotorynski, E., Scherer, S.W., et al. (2002) A Role for Common Fragile Site Induction in Amplification of Human Oncogenes. Cancer Cell, 1, 89-97. https://doi.org/10.1016/S1535-6108(02)00017-X
|
[21]
|
Drilon, A., Cappuzzo, F., Ou, S.I., et al. (2017) Targeting MET in Lung Cancer: Will Expectations Finally Be MET? Journal of Thoracic Oncology, 12, 15-26. https://doi.org/10.1016/j.jtho.2016.10.014
|
[22]
|
Schubart, C., Stöhr, R., Tögel, L., et al. (2021) MET Amplification in Non-Small Cell Lung Cancer (NSCLC)—A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting. Cancers, 13, Article 5023. https://doi.org/10.3390/cancers13195023
|
[23]
|
Peng, L.-X., Jie, G.-L., Li, A.-N., et al. (2021) MET Amplification Identified by Next-Generation Sequencing and Its Clinical Relevance for MET Inhibitors. Experimental Hematology & Oncology, 10, Article No. 52. https://doi.org/10.1186/s40164-021-00245-y
|
[24]
|
Cappuzzo, F., Jänne, P.A., Skokan, M., et al. (2009) MET Increased Gene Copy Number and Primary Resistance to Gefitinib Therapy in Non-Small-Cell Lung Cancer Patients. Annals of Oncology, 20, 298-304. https://doi.org/10.1093/annonc/mdn635
|
[25]
|
Camidge, D.R., Otterson, G.A., Clark, J.W., et al. (2021) Crizotinib in Patients with MET-Amplified NSCLC. Journal of Thoracic Oncology, 16, 1017-1029. https://doi.org/10.1016/j.jtho.2021.02.010
|
[26]
|
Wolf, J., Seto, T., Han, J.Y., et al. (2020) Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 383, 944-957. https://doi.org/10.1056/NEJMoa2002787
|
[27]
|
Engelman, J.A., Zejnullahu, K., Mitsudomi, T., et al. (2007) MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, 316, 1039-1043. https://doi.org/10.1126/science.1141478
|
[28]
|
Chmielecki, J., Mok, T., Wu, Y.L., et al. (2023) Analysis of Acquired Resistance Mechanisms to Osimertinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer from the AURA3 Trial. Nature Communications, 14, Article No. 1071. https://doi.org/10.1038/s41467-023-35962-x
|
[29]
|
Coleman, N., Hong, L., Zhang, J., et al. (2021) Beyond Epidermal Growth Factor Receptor: MET Amplification as a General Resistance Driver to Targeted Therapy in Oncogene-Driven Non-Small-Cell Lung Cancer. ESMO Open, 6, Article 100319. https://doi.org/10.1016/j.esmoop.2021.100319
|
[30]
|
Dagogo-Jack, I., Yoda, S., Lennerz, J.K., et al. (2020) MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clinical Cancer Research, 26, 2535-2545. https://doi.org/10.1158/1078-0432.CCR-19-3906
|
[31]
|
Guo, R., Berry, L.D., Aisner, D.L., et al. (2019) MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. Journal of Thoracic Oncology, 14, 1666-1671. https://doi.org/10.1016/j.jtho.2019.06.009
|
[32]
|
Liam, C.K., Ahmad, A.R., Hsia, T.C., et al. (2023) Randomized Trial of Tepotinib plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clinical Cancer Research, 29, 1879-1886. https://doi.org/10.1158/1078-0432.CCR-22-3318
|
[33]
|
Paik, P.K., Drilon, A., Fan, P.D., et al. (2015) Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping. Cancer Discovery, 5, 842-849. https://doi.org/10.1158/2159-8290.CD-14-1467
|
[34]
|
Kim, T.M., Guarneri, V., Jye, V.P., et al. (2023) OA21.05 Tepotinib Osimertinib in EGFR-Mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis. Journal of Thoracic Oncology, 18, S94. https://doi.org/10.1016/j.jtho.2023.09.106
|
[35]
|
Lu, S., Fang, J., Li, X., et al. (2021) Once-Daily Savolitinib in Chinese Patients with Pulmonary Sarcomatoid Carcinomas and Other Non-Small-Cell Lung Cancers Harbouring MET Exon 14 Skipping Alterations: A Multicentre, Single-Arm, Open-Label, Phase 2 Study. The Lancet Respiratory Medicine, 9, 1154-1164. https://doi.org/10.1016/S2213-2600(21)00084-9
|
[36]
|
Lu, S., Yu, Y., Guo, Q., et al. (2023) OA21.03 a Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation. Journal of Thoracic Oncology, 18, S92-S93. https://doi.org/10.1016/j.jtho.2023.09.104
|
[37]
|
Sequist, L.V., Han, J.-Y., Ahn, M.-J., et al. (2020) Osimertinib plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small-Cell Lung Cancer after Progression on EGFR Tyrosine Kinase Inhibitors: Interim Results from a Multicentre, Open-Label, Phase 1b Study. The Lancet Oncology, 21, 373-386. https://doi.org/10.1016/S1470-2045(19)30785-5
|
[38]
|
Leighl, N., Cho, B.C., Hiret, S., et al. (2023) OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study. Journal of Thoracic Oncology, 18, S93-S94. https://doi.org/10.1016/j.jtho.2023.09.105
|
[39]
|
Cho, B.C., Felip, E., Spira, A.I., et al. (2023) LBA14 Amivantamab plus Lazertinib vs Osimertinib as First-Line Treatment in Patients with EGFR-Mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): Primary Results from MARIPOSA, a Phase III, Global, Randomized, Controlled Trial. Annals of Oncology, 34, S1306. https://doi.org/10.1016/j.annonc.2023.10.062
|
[40]
|
Lee, S.H., Cho, B.C., Spira, A.I., et al. (2023) MA13.06 Amivantamab, Lazertinib plus Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC: Updated Results from CHRYSALIS-2. Journal of Thoracic Oncology, 18, S146-S147. https://doi.org/10.1016/j.jtho.2023.09.208
|
[41]
|
Passaro, A., Cho, B.C., Wang, Y., et al. (2023) LBA15 Amivantamab plus Chemotherapy (with or without Lazertinib) vs Chemotherapy in EGFR-Mutated Advanced NSCLC after Progression on Osimertinib: MARIPOSA-2, a Phase III, Global, Randomized, Controlled Trial. Annals of Oncology, 34, S1307. https://doi.org/10.1016/j.annonc.2023.10.063
|